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Background: Chronic periodontitis (CP), atherosclerotic and aortic aneurysmal vascular diseases (VD) are
chronic inflammatory conditions with multifactorial etiologies, including involvement of predisposing genetic
factors. In a previous study, polymorphisms in the gene for the anti-inflammatory interleukin-1 receptor
antagonist were associated with CP in patients with VD.
Objective: This study investigates whether polymorphisms in the gene for the anti-inflammatory interleukin-
10 (IL10) could be related to CP in the same manner.
Methods: Seventy-two patients with VD of whom 35 had CP were genotyped for single nucleotide
polymorphisms (SNPs) in the IL10 592 (rs1800872), 819 (rs1800871), and 1,082 (rs1800896) gene by
Taqman rtPCR method and by DNA sequencing.
Results: The C alleles and C/C genotypes of IL10 592 and IL10 819 frequencies were significantly
higher, while the frequencies of the IL10 592 (C/A) and IL10 819 (C/T) heterozygote genotypes were
significantly lower in the VD group with CP compared to those without CP. The IL10 haplotype ATA
frequency (1,082, 819, 592) showed a trend to a significant difference between the two groups indicating
protection against CP.
Conclusions: Taken together, our findings suggest an independent association of genetic polymorphisms in the
IL-10 gene locus with CP in patients with VD. Development of CP and the implications on vascular disease
emphasize the importance of early detection and adequate treatment of periodontitis among these patients.
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C
hronic periodontitis (CP) and atherosclerotic
and aortic aneurysmal vascular diseases (VD)
are highly prevalent chronic inflammatory condi-
tions. They cause tooth loss, ischemic stroke, myocardial
infarction, and aneurysmal rupture and have therefore
considerable consequences and cost, both at individual
and societal levels (13).
These diseases are complex and multifactorial and share
common risk factors such as age, smoking, and diabetes
mellitus (4, 5). However, an association between CP and
atherosclerotic vascular conditions has been reported,
independent of confounding factors, and the impact of
CP on systemic health is suggested to be an additional
risk factor for initiation and progression of VD (57).
Familial and twin studies have shown genetic predis-
position to periodontal diseases and VD (3, 8, 9). Due to
the chronic inflammatory characteristics and similarities
in risk factors, it has been suggested that a shared genetic
risk profile can partly underlie the association found in
the literature. Candidategene association studies have
identified shared genetic susceptibility loci (1012), but
also specific genetic patterns of predisposition for period-
ontal and atherosclerotic VD (4, 10, 11, 13, 14).
The interleukin-1 receptor antagonist (IL-1Ra encoded
by the IL1RN gene) acts as an anti-inflammatory cytokine
by binding to cellular interleukin-1 (IL-1) receptors (15).
In previous studies, we investigated the frequency of
polymorphisms in the IL-1 gene cluster in patients with
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VD and could observe an association between a variable
number of tandem repeat (VNTR) in intron 2 of the
IL1RN gene and CP among patients with VD (16).
IL-10 is another anti-inflammatory cytokine with
important immunoregulatory functions. IL-10 is mainly
produced by monocytes, macrophages, and CD4 Th2
cells, but may be produced by almost all leukocytes,
and exhibits a wide range of biological effects. Primarily,
IL-10 inhibits the release of pro-inflammatory mediators
such as tumor necrosis factor alpha (TNF-a), IL-1b,
IL-6, and IL-8 from monocytes/macrophages and inhi-
bits the proliferation and the cytokine synthesis of
activated CD4 T cells. Further, IL-10 constrains antigen
presentation of monocytes/macrophages by reducing the
cell surface expression of major histocompatibility com-
plex class II (MHC II), co-stimulating, and adhesion
molecules (17). Additionally, it enhances the production
of anti-inflammatory mediators such as IL-1 receptor
antagonist (18). It also has important actions on B-cells
by preventing apoptosis, enhancing proliferation and
differentiation, increasing MHC II expression, and facil-
itating immunoglobulin class switching (17, 19).
Higher levels of IL-10 mRNA are expressed in gingival
biopsies from patients with CP as compared with healthy
control biopsies (20). In murine models, IL-10 knockout
mice were found to be highly susceptible to severe alveolar
bone loss as compared with wild-type mice (21). In addi-
tion to the inhibition of inflammation in periodontal
disease, IL-10 may moderate tissue destruction by mod-
ulating matrix metalloproteinase (MMPs) and osteoclas-
togenesis through regulation of the receptor activator
of nuclear factor-kappaB ligand (RANKL), colony-
stimulating factor-1 (CSF-1), and osteoprotegerin (OPG)
expression (22, 23). Furthermore, in an experimental
periodontal model, IL-10 levels in periodontal tissue
were associated with higher expression of tissue inhibitors
of metalloproteinases (TIMPs) and inhibitor of osteoclas-
togenesis OPG, and lower expression of MMPs and
RANKL, and with lower cellular infiltration in period-
ontal tissues and alveolar bone loss (24).
It is estimated that 5080% of the differences in the
IL-10 production can be explained by genetic factors
(25). The single nucleotide polymorphisms (SNPs) in the
promoter region of interleukin-10 (IL10) gene at positions
592, 819 and 1,082 are associated with altered
IL-10 levels (2628), and several studies have investigated
the association between these polymorphisms and period-
ontal diseases (9, 25, 29), but with inconsistent results.
CP can, through systemic changes, cause an additional
burden in the pathogenesis of VD. Severe periodontal
disease is associated with endothelial dysfunction (mea-
sured by impaired flow-mediated dilation) (30), and in a
recent prospective study, improvement in periodontal
status was correlated with decreased progression of carotid
artery media thickness at 3-year follow-up (7). These
findings emphasize the importance of early identifica-
tion of patient populations that can benefit from period-
ontal intervention to prevent progression of VD. Previous
studies have reported association between polymorphisms
in genes for IL-1 (10), IL-1Ra (16), and TNF-a (14) with
CP in patients with atherosclerotic and aneurysmal VD.
The functional IL-10 SNPs have not been investigated for
CP in patients with vascular conditions. Thus, this study
investigates the potential role of polymorphisms in the
IL10 promoter region for independent association with
CP in Scandinavian patients with severe vascular disease
in the major arteries.
Material and methods
Participants
The study included a total of 67 Norwegian, 3 Swedish,
and 2 Danish VD patients. The patients were recruited
at the Department of Vascular Surgery, Oslo University
Hospital, Aker, and were seeking surgical treatment for
abdominal aorta aneurism repair, carotid or femoral endar-
terectomy, or percutaneous transluminal angioplasty of
the femoral arteries.
Clinical oral examinations were performed at the
hospital ward to determine the periodontal status of the
patient. The patients were categorized into two groups.
The first group (VD with CP) was made up of patients
undergoing treatment for VD and diagnosed with CP
(n35, mean age67.9, SD6.9, range: 51.385.0).
The second group (VD without CP) was made up of
patients undergoing treatment for VD who were assessed
without CP (n37, mean age71.1, SD7.8, range:
55.484.8). Demographic data of the study groups are
shown in Table 1.
The patients’ medical records were obtained for general
health information. Ethnicity and smoking behavior
were self-reported. Written informed consent was ob-
tained from all participants; the study was approved by
the Regional Ethical Committee (REK Sør, NO. 08/322b)
and was in accordance with the Helsinki declaration of
1975, as revised in 2008. The study has been registered at
ClinicalTrials.gov (ID. NCT01358630).
Inclusion criteria
The patients in both groups were diagnosed and treated
according to standard procedures at the Department
of Vascular Surgery, Oslo University Hospital. Diagnosis
of CP was based on the classification system of the
American Academy of Periodontology, established in
1999 at the International Workshop for Classification
of Periodontal Diseases and Conditions (31). Clinical
periodontal status was assessed by a trained dentist
(Armingohar) as previously described (16).
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Samples and DNA isolation
Vascular biopsies and saliva samples were collected
for extraction of genomic DNA. The vascular biopsies
were collected under surgical treatment from the walls of
aneurisms and during excision of intravascular plaques in
carotid or common femoral arteries.
Saliva samples were collected with the OrageneTM DNA
Self-Collection Kit (Genotek, Ottawa, Ontario, Canada)
according to the manufacturer’s instructions. Extraction
of genomic DNA was performed using the Masterpure
Complete DNA Purification Kit (Epicentre Biotechnol-
ogies, Madison, WI, USA) as previously described (16).
Analyses of DNA polymorphisms
SNP allele discrimination assays were performed by the
real-time polymerase chain reaction (PCR) amplification
method. The alleles of IL10 at 592 (rs 1800872) and
1,082 (rs1800896), were detected by 5’nuclease allelic
discrimination Taqman method using Assays by Design/
Demand (Applied Biosystems, Foster City, CA, USA)
with locus-specific forward and reverse primers and two
allele-specific oligonucleotide probes for each SNP of
interest (Table 2), according to manufacturer’s instructions.
The alleles of IL10 819 (rs1800871) were detected by
5? nuclease allelic discrimination method using locus-
specific forward and reverse primers and two allele-
specific oligonucleotide probes for each SNP of interest
(Table 2; Biochemistry Department, University of Oslo,
Oslo Research Park) as described previously (32). The
probes for each allele (listed in Table 2) were labeled with
FAM or VIC at the 5? end, and non-fluorescent quencher
or ‘black-hole’ quencher at the 3? end. The experiments
were performed in the Mx-3005p (Agilent Technologies
Inc., USA) using the TaqMan Universal PCR Master
Mix (Applied Biosystems), along with approximately 20 ng
DNA template.
To confirm the results of the Taqman genotyping, part
of the IL-10 promoter region covering the SNP loci of
interest was PCR amplified and sequenced. PCR reac-
tions were performed with forward primer 5?-ACAAATC
CAAGACAACACTACTAAG-3? and reverse primer 5?-
ATGAATACCCAAGACTTCTCCTTGCTA-3? Sigma-
Aldrich, MO, USA), and OneTaq 2X Master Mix (New
England Biolabs, Beverly, MA, USA) at an annealing
temperature of 558C. The PCR products were purified by
Exosap-IT (Affymetrix, Santa Clara, CA, USA) accord-
ing to the manufacturer’s protocol. Purified amplicons
were sequenced using the BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems) and the forward
and revers primers. Sequence reactions were run on an
ABI Prism 3730 DNA analyzer (Applied Biosystems).
Sequence trimming, quality check and alignment were
performed with the Sequencher 5.0 program (Gene Codes
Corp., Ann Arbor, MI).
Statistical analyses
The statistical analyses were performed using the SPSS
software (IBM SPSS Statistic version19) and JavaStat
(http://statpages.org/). Chi-square and Fisher’s exact tests
were used for univariate comparisons of allelic and geno-
typic frequencies of the SNP loci between the groups.
Binary logistic regression was used to adjust the genotypic
differences for the effect of age, gender, body mass index
(BMI), diabetes, and smoking status. The genotype
analyses were performed by comparing each genotype
frequency to the pooled total of the other groups. The
assembly and prediction of haplotypes for the IL10
SNP cluster were done by the software ‘Phase’ (33). All
loci were in HardyWeinberg equilibrium. A statistically
significant difference was defined when p wasB0.05.
Results
Genotyping was successful in all but two patients, who
were excluded from further analysis.
In Table 3, allelic and genotypic frequencies of the
SNPs IL10 592, 819 and 1,082 are listed.
Using chi-square tests, a significant difference in allelic
frequencies was found between the two study groups
Table 1. Demographic data of the patients with athero-
sclerotic and aortic aneurysmal vascular diseases (VD) with
(w/) and without (wo/) chronic periodontitis (CP)
VD w/CP VD wo/CP
Age n35 n37
Mean9SD 67.996.9 71.197.8
Median (minmax) 67.6 (51.385.0) 71.2 (55.484.8)
Gender (n)
Male 29 30
Female 6 7
Teeth (n)
Mean9SD 18.597.4 24.992.3
Median (minmax) 20 (428) 25 (2029)
Periodontal pocket probing
depth (n]5 mm)
Mean9SD 15.6910.9 0.790.99
Median (minmax) 11 (455) 0 (03)
Diabetes (n) 3 13
Smoking (n)
Non-smokers 1 9
Current or previously
smokers
34 28
Pack-year Mean9SD 37.0919.6 25.1914.5
Pack-year Median
(minmax)
34.7 (4.988.0) 23.6 (3.151.3)
Body mass index (kg/m2)
Mean9SD 26.494.2 27.094.5
Median (minmax) 26.4 (14.235.3) 26.5 (18.337.0)
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regarding IL10 592 (p0.03, OR2.23, 95% CI
1.074.68) and IL10 819 (p0.047, OR2.1, 95%
CI1.0034.42) with the C allele being more frequent in
the VD group with CP.
The frequencies of the IL10 592 genotype 1/1 (C/C)
showed a significant difference (chi-square, p0.01,
OR3.53, 95% CI1.339.31) comparing the group
of VD patients with CP (n22) with the group of VD
patient without CP (n12). After adjustment for the
risk factors age, gender, BMI, diabetes and smoking
status by logistic regression, this difference was signifi-
cant (p0.02, OR4.0, 95% CI1.2812.35), indicat-
ing a significant association of the IL10 592 C/C
genotype with risk for CP among VD patients.
The heterozygote IL10 592 genotype 1/2 (C/A) fre-
quencies displayed a statistical significant difference com-
paring the two groups of patients (chi-square, p0.02,
OR0.31, 95% CI0.120.82), being lower in the VD
patients with CP (n11) compared to those without
CP (n22). This difference was significant (p0.02,
OR0.26, 95% CI0.080.82) in the logistic regression
model, indicating a protection against periodontitis among
VD patients with the IL10 592 1/2 genotype.
The IL10 592 genotype was significantly associated
with CP in an overall analysis of the individual genotypes
using chi-square (p0.03). This association remained
borderline significant in a logistic regression model
(p0.05) (results not shown).
The IL10 819 genotype 1/1 (C/C) showed a signifi-
cantly different frequency between the two groups (chi-
square, p0.02, OR3.12, 95% CI1.198.2), being
higher in the VD with CP group (n22) than in the VD
without CP group (n13). When adjusted for the risk
by logistic regression, this difference remained significant
(p0.02, OR3.69, 95% CI1.211.4), indicating a
possible association of the IL10 819 C/C genotype with
risk for CP among VD patients.
The frequencies of the heterozygote IL10 819 geno-
type 1/2 (C/T) displayed statistical significant difference
comparing the VD patients with CP group (n11) with
those without CP (n21) (chi-square, p0.03, OR
0.35, 95% CI0.130.92). This difference was significant
in the logistic regression model (p0.03, OR0.28, 95%
CI0.090.88) suggesting protection against CP among
VD patients with the IL10 819 1/2 genotype.
No significant allelic or genotypic frequency differ-
ences in the IL10 1,082 SNP were detected comparing
the VD patients with and without CP (p0.05).
Haplotype analysis using Phase software predicted
four different haplotypes as shown in Table 4. The
predicted IL10 haplotype ATA (1,082, 819, 592)
designated as 1-2-2 showed a borderline significant dif-
ference comparing the two patient groups (chi-square,
p0.047, OR0.47, 95% CI0.211.06), possibly in-
dicating protection against periodontitis compared to
the other haplotypes.
In the logistic regression analysis no statistically sig-
nificant correlations were found between the risk factors
age, gender, BMI, diabetes and smoking status.
The results from SNP genotyping using real-time PCR
amplification method and by DNA sequencing were in
agreement.
Discussion
CP has been associated with VD and is suggested to be
an additional risk factor for cardiovascular diseases
independent of confounding factors (5, 6). Polymorph-
isms in inflammatory genes have been investigated for
association with periodontal and cardiovascular disease
susceptibility, and both shared (1012) and distinct genetic
associations (4, 10, 11, 13, 14) have been identified.
Here, we investigated whether polymorphisms in the IL-
10 gene promoter region can be associated to CP among
patients with VD. Three functional SNPs in the promoter
region of the IL10 at positions 1,082 (AG), 819
(CT) and 592 (CA) are reported to have a regu-
latory function on promoter activity (26), and are asso-
ciated with altered IL-10 production (28, 34). These SNPs
Table 2. Primer and probe sequences used to detect nucleotide polymorphisms in this study
Gene Location Polymorphism Primers/Probes
IL10 Promoter SNP 592 CA (rs1800872) VIC/FAM: CTTTCCAGAGACTGGCTTCCTACAG[G/T]ACAGGCGG
GGTCACAGGATGTGTTC
IL10 Promoter SNP 819 CT (rs1800871) Fw: 5? GGCACTGGTGTACCCTTGTA 3?
Rv: 5? CATGACCCCTACCGTCTCTATTTT 3?
FAM: 5? AGGCACAGAGATATTACAT 3?
VIC: 5? AGGCACAGAGATGTTACAT 3?
IL10 Promoter SNP 1,082 AG (rs1800896) VIC/FAM: TCCTCTTACCTATCCCTACTTCCCC[T/C]TCCCAAAGA
AGCCTTAGTAGTGTTG
SNP, single nucleotide polymorphism; Fw, forward primer; Rv, reverse primer.
Taqman probes are listed with the polymorphic bases in bold.
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have been investigated for association with CP suscep-
tibility, but with inconsistent results (9, 29). Ethnic
differences in IL10 allele and genotype frequencies may
be a reason for the discrepancy in reported results; hence
only Scandinavian patients were included in the present
study (35).
The IL10 SNP at position 592 (CA) is located
in a negative regulatory region, the 819 (CT) poly-
morphism may affect an estrogen receptor element (34),
while the IL10 1,082 (AG) SNP lies within a putative
e-twenty-six ETS like-transcription binding site and may
influence transcriptional activity (27). Larsson et al.
Table 3. Allele and genotype frequencies within the IL10 gene locus in patients with atherosclerotic and aortic aneurysmal
vascular disease (VD) with (w/) or without (wo/) chronic periodontitis (CP)
Allele frequency
VD w/CP VD wo/CP
p (VD w/CP vs. VD wo/CP)
(chi-square)
IL10a SNP 1082 rs1800896 n70 n74
1 A 0.53 (37)c 0.64 (47) 0.2
2 G 0.47 (33) 0.36 (27)
IL10a SNP 819 rs1800871 n70 n74
1 C 0.79 (55) 0.64 (47) 0.047d
2 T 0.21 (15) 0.36 (27)
IL10a SNP 592 rs1800872 n70 n74
1 C 0.79 (55) 0.62 (46) 0.03e
2 A 0.21 (15) 0.38 (28)
Genotype frequency
VD w/CP VD wo/CP p (VD w/CP vs. VD wo/CP)
(chi-square)
p (VD w/CP vs. VD wo/CP)
(logistic regression model)
IL10b SNP 1082 rs1800896 n35 n37
1/1 A/A 0.26 (9)c 0.35 (13) 0.39 0.23
1/2 A/G 0.54 (19) 0.57 (21) 0.83 0.94
2/2 G/G 0.20 (7) 0.08 (3) 0.18 0.14
IL10b SNP 819 rs1800871 n35 n37
1/1 C/C 0.63 (22) 0.35 (13) 0.02f 0.02g
1/2 C/T 0.31 (11) 0.56 (21) 0.03h 0.03i
2/2 T/T 0.06 (2) 0.08 (3) 1 0.8
IL10b SNP 592 rs1800872 n35 n37
1/1 C/C 0.63 (22) 0.32 (12) 0.01j 0.02k
1/2 C/A 0.31 (11) 0.59 (22) 0.02l 0.02m
2/2 A/A 0.06 (2) 0.08 (3) 1 0.8
SNP, single nucleotide polymorphism.
aAllele designation (1 more frequent, major allele; 2less frequent, minor allele).
bGenotype designations.
cNumber of alleles and genotypes in parentheses.
dOR0.52, 95% CI1.0034.42.
eOR2.23, 95% CI1.074.68.
fOR3.12, 95% CI1.198.2.
gOR3.69, 95% CI1.211.4.
hOR0.35, 95% CI0.130.92.
iOR0.28, 95% CI0.090.88.
jOR3.53, 95% CI1.339.31.
kOR4.0, 95% CI1.2812.35.
lOR0.31, 95% CI0.120.82.
mOR0.26, 95% CI0.080.82.
In the binary logistic regression model the genotypic differences were adjusted for the effect of age, gender, body mass index, diabetes,
and smoking status.
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showed that the transcription factor Sp1 only bound to
the G allele at the 1,082 position in the IL-10 promoter
region resulting in higher IL-10 and Sp1 mRNA expres-
sion for GG genotypes in B-cells (28). The three SNPs
are in close linkage disequilibrium, with three main pre-
ference haplotypes (1,082, 819, 592): GCC, ACC
and ATA (26, 34). The GCC haplotype is associated with
high, the ATA haplotype with low and the ACC with an
intermediate IL-10 production (36, 37).
Claudino et al. have shown in their study that both
IL10 592 CA and AA genotypes were more frequent
in patients with CP, and that these genotypes were
associated with disease severity and lower levels of
IL-10, tissue inhibitor of metalloproteinase-3 (TIMP-3),
and the inhibitor of osteoclastogenesis OPG mRNA
expression in diseased periodontal tissues (22). Cullinan
et al. investigated the possible association between IL-10
gene polymorphisms and periodontal disease progression
in a prospective longitudinal study in an Australian
population. They reported that individuals having either
the ATA/ACC or the ACC/ACC genotype experienced
less periodontal disease progression after 5 years com-
pared to individuals with other genotypes (38).
In our patients, the putative high IL-10 producer
alleles (819 C and 592 C) and genotypes (819 C/C
and 592 C/C) were associated with CP, while the low
producer ATA haplotype showed a trend to protection
against CP. In addition, the G allele and G/G genotype
of the IL 1,082 were more frequent among CP patients,
but this difference did not reach a significant level com-
paring the two groups. In contrast to our study, the alleles
IL10 819 T and 592 A, which are connected with
low IL-10 levels, have been associated with risk for CP
in other Caucasian populations (29, 39). Similar to our
study, the high IL10 producer G allele and GG genotype
of IL 1,082 have been found to be associated with CP
in a Swedish population (40). While in other studies,
the low producer A allele of 1,082 has also been asso-
ciated with risk for CP (41, 42). These previous findings
compared to our findings, suggest that studying popula-
tions of similar ethnicity show more consistency and
reproducibility. This could be due to increase of IL10
genetic effect size in the Scandinavian (Nordic) popula-
tion(s) from natural selection and/or variable exposures
to environmental and other factors affecting immuno-
competence in CP and VD.
It is plausible that IL-10 can reduce clearance of
infectious pathogens by suppressing the protective innate
and adaptive immune responses, and therefore is involved
in the persistence of bacteria and chronic infections
(19, 43). Murine models of infectious diseases have shown
that even normal levels of IL-10 tend to limit the efficiency
of immune responses against pathogens, and that the
resistance to infection can be improved by reducing IL-10
levels (44). Additionally, IL-10 enhances the release of
anti-inflammatory mediators such as IL-1 receptor an-
tagonist (18). In a previous study, we found a significantly
higher frequency of the allele 1 and a higher frequency
of allele 2 of the ILIRN VNTR among CP patients with
VD (16). Association studies have shown that homozy-
gous carriers of allele 2 of the IL-1Ra gene have a longer
and more severe pro-inflammatory immune response than
persons with other IL1RN genotypes (15). Thus, it is
conceivable that the carriage of allele 2 can be beneficial
in combating microbial challenges in the gingival sulcus.
Indeed, allele 2 carriers have shown reduced vaginal
colonization by mycoplasma and resistance to human
cytomegalovirus and Epstein-Barr virus (15). Together,
these findings indicate that excessive down-regulation of
the pro-inflammatory mechanisms could result in reduced
efficiency of anti-pathogenic immune responses in period-
ontal disease. The genotype of CP patients in this study
and our previous study (16), associated with excessive anti-
inflammatory responses and potentially reduced pathogen
clearance, can therefore be detrimental in periodontal
disease susceptibility.
The number of patients in the present study was limited
because it is difficult to recruit patients with life-threatening
Table 4. Estimated IL10 locus haplotype frequencies in patients with atherosclerotic and aortic aneurysmal vascular disease
(VD) with (w/) or without (wo/) chronic periodontitis (CP)a
Haplotype designations
VD w/CP
n(70)
VD wo/CP
n(74)
Numericb Otherc Frequency group (n) Frequency group (n) P (chi-square) OR (95% CI)
211 G-C-C 0.471 (33) 0.365 (27) 0.195
111 A-C-C 0.314 (22) 0.257 (19) 0.445
122 A-T-A 0.214 (15) 0.365 (27) 0.047 OR0.47 (CI0.211.06)
112 A-C-A 0 (0) 0.014 (1) 1
aEstimation of population frequencies of predicted haplotypes.
bIL10 (1,082), IL10 (819), and IL10 (592) haplotype designation.
cNucleotide designation of listed SNP allele numbers.
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VD, being prepared for major surgery. Sample size is
associated with the power of statistical tests. Post hoc
power calculations showed that the power of our tests was
low. The consequence is an increase in the risk for type
II error, the possibility that potential differences between
groups might not be detected. Yet, we have found a statis-
tically significant difference between the study groups
regarding the IL10 819 and 592 independent of
shared risk factors, indicating that in persons with VD,
genotypes of inflammatory factors within the IL-10 gene
cluster are associated with CP.
Animal studies and in vitro studies on human aortic
endothelial cells have shown anti-atherogenic properties
of IL-10 (45, 46). Genotype and haplotype variants
within the IL10 gene have been associated with athero-
sclerotic diseases, but with discrepant results (47, 48).
Our findings, however, suggest that these gene variants
still can have a stronger association to CP than VD.
The development of CP may constitute additional
burden in the pathogenesis of VD by causing sustained
low-graded systemic inflammation and bacterial dissem-
ination in the circulation (49). In this study, we have
identified genetic markers that are specifically associated
with CP within a group of patients with VD. Information
about these genetic components or predictive biomarkers
may help to identify subgroup of VD patients who are at
risk to develop CP, and selectively target them for effective
preventive CP interventions.
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